<DOC>
	<DOCNO>NCT01067859</DOCNO>
	<brief_summary>A placebo control , double-blind randomize study assess different dos new drug ( BAY58-2667 ) give intravenously , evaluate safe help improve well-being patient acute decompensated heart failure .</brief_summary>
	<brief_title>A Phase IIb Study Investigate Efficacy Tolerability Lower Doses Cinaciguat ( 25 µg/h , 10 µg/h ) Given Intravenously Patients With Acute Decompensated Chronic Congestive Heart Failure ( ADHF )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Male nonpregnant , nonlactating female subject , age &gt; /= 18 year age ; woman without childbearing potential define postmenopausal woman age 55 year old , woman bilateral tubal ligation , woman bilateral ovariectomy , woman hysterectomy Subjects must clinical diagnosis Congestive Heart Failure ( CHF ) make least three month prior enrollment Subjects must experience worsen symptom lead hospitalization time entry study : dyspnea clinical evidence volume overload Acute denovo heart failure Acute myocardial infarction and/or myocardial infarction within 30 day Valvular heart disease require surgical intervention course study Heart failure due associate uncorrected primary valvular disease , malfunction artificial heart valve , uncorrected congenital heart disease Primary hypertrophic cardiomyopathy Acute inflammatory heart disease , eg , acute myocarditis Unstable angina require angiography</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Heart Failure</keyword>
</DOC>